Sava Infond d.o.o. Acquires New Stake in IQVIA Holdings Inc. (NYSE:IQV)

Sava Infond d.o.o. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,250 shares of the medical research company's stock, valued at approximately $2,014,000.

Other large investors also recently modified their holdings of the company. Private Trust Co. NA raised its holdings in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after buying an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co raised its holdings in shares of IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after acquiring an additional 50 shares during the last quarter. Howard Capital Management Inc. lifted its position in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares in the last quarter. Finally, Cypress Wealth Services LLC raised its stake in shares of IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after purchasing an additional 57 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Remove Ads

IQVIA Stock Performance

Shares of NYSE:IQV traded down $4.39 during trading on Monday, hitting $173.00. 651,435 shares of the company were exchanged, compared to its average volume of 1,456,849. IQVIA Holdings Inc. has a 52-week low of $169.37 and a 52-week high of $253.84. The stock has a 50 day moving average of $193.15 and a 200 day moving average of $206.05. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $30.50 billion, a PE ratio of 23.08, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on IQV shares. UBS Group decreased their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Stephens assumed coverage on shares of IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.